A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

General Inclusion Criteria:

≥ 18 years of age
Adequate organ function
Life expectancy ≥ 16 weeks
Women of childbearing potential must have a negative serum pregnancy test
High-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer
Received 1 or 2 prior regimens, including ≥ 1 prior platinum-based therapy and have platinum-sensitive disease
Relapsed/progressive disease (confirmed by radiologic assessment)
Willing and able to have a biopsy of tumor at screening and after 4 weeks of treatment.
Measurable disease (RECIST v1.1)- Cohort A1 only
ECOG performance status of 0 to 1

General Exclusion Criteria

Active second malignancy
Central nervous system brain metastases
Evidence of interstitial lung disease, active pneumonitis, myocarditis, or history of myocarditis.
Active, known or suspected autoimmune disease (eg, autoimmune hepatitis).
Condition requiring systemic treatment with either corticosteroids
Prior treatment with a PARP inhibitor or immune checkpoint inhibitor.
Non-epithelial tumors (pure sarcomas) or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors. Mixed Mullerian tumors/carcinosarcomas are allowed.